Tag: 2026
Novo Nordisk’s Etavopivat Cracks Phase 3 Goals: A Potential New Standard of Care for Sickle Cell Disease
Novo Nordisk’s Etavopivat hits the mark in Pivotal Sickle Cell Study. Etavopivat, an oral, once-daily pyruvate kinase-R (PKR) activator displayed supercilious results showing 27%...